Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 765049 and BI 765049 + BI 754091 Administered by Repeated Intravenous Infusions in Patients with Malignant Solid Tumors, including Pancreatic Cancer Expressing B7-H6
The purpose of this Phase I study is to evaluate the safety and tolerability of BI 765049 alone and in combination with BI 754091 in patients with advanced solid tumors, including pancreatic cancer.
Study ID: 1454-0001
Trial Phase: Phase I
Trial Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.
Therapies Used in This Trial: BI 765049, BI 754091